A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
By Jingyun Yang, Wei Wang, Zimin Chen, Shuaiyao Lu, Fanli Yang, Zhenfei Bi, L. Bao, Fei Mo, Xue Li, Yong Huang and 75 more. Nature, 2020
724 citations recorded by the source corpus.
Subfields: Animal Science and Zoology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/4a8e95f3161fe0cb0a950b10f3f25c853f7b68bb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Xuemei He
- Yu-long Cai
- Yuquan Wei
- Tingmei Zhao
- Yifan Yu
- Yujie Jiang
- Xiaohe Tian
Citations in the corpus
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding (2020, neutral): “, 2020), and several promising vaccine candidates use the RBD as the sole antigen (Chen et al., 2020a, 2020b; Mulligan et al., 2020; Quinlan et al., 2020; Ravichandran et al., 2020; Yang et al., 2020; Zang et al., 2020).”
- Vaccine adjuvants: mechanisms and platforms (2023, background): “In addition, aluminum is also a candidate adjuvant for vaccines in new clinical development, such as the SARS-CoV-2 vaccine.(143,144) However, aluminum adjuvants also have some disadvantages, including difficulties in inducing a strong cellular immune response and the possibility of adverse reaction”